Mersana Therapeutics, Inc. financial data

Symbol
MRSN on Nasdaq
Location
Cambridge, MA
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 172% % -42%
Debt-to-equity -364% % -139%
Return On Equity 183% %
Return On Assets -69% % -80%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4,998,750 shares -96%
Common Stock, Shares, Outstanding 4,998,500 shares -96%
Entity Public Float $226,275,877 USD -38%
Common Stock, Value, Issued $0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 4,992,639 shares 1.7%
Weighted Average Number of Shares Outstanding, Diluted 4,992,639 shares 1.7%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $33,180,000 USD -4.8%
Research and Development Expense $69,027,000 USD -4.4%
General and Administrative Expense $31,529,000 USD -25%
Nonoperating Income (Expense) $1,426,000 USD -75%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $7,545,000 USD 32%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $70,081,000 USD 6.1%
Earnings Per Share, Basic 0 USD/shares 35%
Earnings Per Share, Diluted 0 USD/shares 35%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $56,391,000 USD -28%
Cash, Cash Equivalents, and Short-term Investments $134,600,000 USD
Accounts Receivable, after Allowance for Credit Loss, Current $168,000 USD -83%
Assets, Current $59,988,000 USD -63%
Property, Plant and Equipment, Net $163,000 USD -93%
Operating Lease, Right-of-Use Asset $2,035,000 USD -62%
Other Assets, Noncurrent $500,000 USD -49%
Assets $62,686,000 USD -63%
Accounts Payable, Current $2,393,000 USD 18%
Employee-related Liabilities, Current $3,887,000 USD -62%
Accrued Liabilities, Current $14,813,000 USD -20%
Contract with Customer, Liability, Current $23,770,000 USD -24%
Liabilities, Current $43,269,000 USD -37%
Contract with Customer, Liability, Noncurrent $78,954,000 USD -5.9%
Operating Lease, Liability, Noncurrent $0 USD -100%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $122,223,000 USD -27%
Accumulated Other Comprehensive Income (Loss), Net of Tax $0 USD -100%
Retained Earnings (Accumulated Deficit) $951,517,000 USD -8%
Stockholders' Equity Attributable to Parent $59,537,000 USD -5776%
Liabilities and Equity $62,686,000 USD -63%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $29,326,000 USD 10%
Net Cash Provided by (Used in) Financing Activities $3,137,000 USD -154%
Net Cash Provided by (Used in) Investing Activities $27,000,000 USD
Common Stock, Shares Authorized 350,000,000 shares 0%
Common Stock, Shares, Issued 4,998,500 shares -96%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $5,463,000 USD 95%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $56,869,000 USD -28%
Interest Paid, Excluding Capitalized Interest, Operating Activities $704,000 USD -19%
Deferred Tax Assets, Valuation Allowance $262,845,000 USD 9.8%
Deferred Tax Assets, Gross $264,098,000 USD 9.3%
Operating Lease, Liability $5,148,000 USD -39%
Payments to Acquire Property, Plant, and Equipment $0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $70,106,000 USD 6%
Lessee, Operating Lease, Liability, to be Paid $5,497,000 USD -42%
Operating Lease, Liability, Current $2,293,000 USD -39%
Lessee, Operating Lease, Liability, to be Paid, Year Two $1,310,000 USD -69%
Lessee, Operating Lease, Liability, to be Paid, Year One $4,187,000 USD 5.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $349,000 USD -67%
Deferred Tax Assets, Operating Loss Carryforwards $122,010,000 USD -3.8%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 25,000,000 shares 0%
Unrecognized Tax Benefits $0 USD
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $316,000 USD -25%
Deferred Tax Assets, Net of Valuation Allowance $1,253,000 USD -40%
Share-based Payment Arrangement, Expense $9,264,000 USD -46%
Interest Expense $4,092,000 USD 14%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%